<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: We examined the effects of <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> treatment on profiles of adipocytokines levels, postprandial insulin and <z:chebi fb="105" ids="17234">glucose</z:chebi> excursion, <z:chebi fb="23" ids="18059">lipids</z:chebi> levels, comparing with those of <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> treatment in patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (T2DM) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Changes in body weight, <z:chebi fb="34" ids="35143">haemoglobin</z:chebi> A(1c )(HbA(1c)), <z:chebi fb="105" ids="17234">glucose</z:chebi>/insulin/C-<z:chebi fb="7" ids="16670">peptide</z:chebi>/free fatty acid (FFA) during 75 g oral <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance test (OGTT), <z:chebi fb="17" ids="39025">HDL</z:chebi>-/<z:chebi fb="1" ids="47774">LDL-cholesterol</z:chebi>, <z:chebi fb="0" ids="17855">triglyceride</z:chebi> (TG) and adipocytokines [<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor (TNF)-alpha, leptin and adiponectin] were measured in T2DM patients treated with <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi>, 8 mg/day (n = 35), or <z:chebi fb="0" ids="8228">pioglitazone</z:chebi>, 45 mg/day (n = 21), for 3 months </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: After <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> or <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> treatment, HbA(1c )(8.6-7.2 vs. 8.3-6.9%, <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> vs. <z:chebi fb="0" ids="8228">pioglitazone</z:chebi>), fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> (190-144 vs. 178-140 mg/dl), fasting FFA (729-595 vs. 641-526 microEq/l), mean plasma <z:chebi fb="105" ids="17234">glucose</z:chebi>-OGTT (292-229 vs. 285-233 mg/dl) and mean FFA-OGTT (580-430 vs. 488-377 microEq/l) decreased similarly and <z:hpo ids='HP_0000001'>all</z:hpo> were statistically significant (p &lt; 0.01) </plain></SENT>
<SENT sid="3" pm="."><plain>The insulinogenic index (DeltaI(0-120)/DeltaG(0-120)) (0.19-0.30 vs. 0.17-0.26) and Matsuda index of insulin sensitivity (2.0-3.1 and 2.7-4.3) increased (p &lt; 0.01) similarly, despite increase in body weight (85-88 vs. 81-84 kg) </plain></SENT>
<SENT sid="4" pm="."><plain>TNF-alpha (3.8-3.4 vs. 5.2-4.5 pg/ml) decreased (p &lt; 0.05) and adiponectin (6.3-17.8 vs. 7.1-16.4 microg/ml) increased (p &lt; 0.01), while leptin did not change following either treatment </plain></SENT>
<SENT sid="5" pm="."><plain>After <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> treatment, plasma <z:chebi fb="4" ids="47775">HDL-cholesterol</z:chebi> (34-38 mg/dl) and <z:chebi fb="1" ids="47774">LDL-cholesterol</z:chebi> (103-120 mg/dl) increased (p &lt; 0.01), while TGs (177-167 mg/dl) did not change significantly </plain></SENT>
<SENT sid="6" pm="."><plain>After <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> treatment, plasma <z:chebi fb="4" ids="47775">HDL-cholesterol</z:chebi> (34-37 mg/dl) increased (p &lt; 0.05), while <z:chebi fb="1" ids="47774">LDL-cholesterol</z:chebi> (104-105 mg/dl) did not change and TGs (153-106 mg/dl) decreased (p &lt; 0.01) </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: <z:chebi fb="0" ids="50122">Rosiglitazone</z:chebi> and <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> have similar beneficial effects on glycaemic control insulin sensitivity, insulin secretion and plasma adipocytokine levels </plain></SENT>
<SENT sid="8" pm="."><plain>However, <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> has a more beneficial effect on the plasma <z:chebi fb="23" ids="18059">lipid</z:chebi> profile than <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> </plain></SENT>
</text></document>